Rajeev Shrimali

2.3k total citations · 1 hit paper
24 papers, 1.5k citations indexed

About

Rajeev Shrimali is a scholar working on Oncology, Immunology and Nutrition and Dietetics. According to data from OpenAlex, Rajeev Shrimali has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Immunology and 7 papers in Nutrition and Dietetics. Recurrent topics in Rajeev Shrimali's work include Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (9 papers) and Selenium in Biological Systems (7 papers). Rajeev Shrimali is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (9 papers) and Selenium in Biological Systems (7 papers). Rajeev Shrimali collaborates with scholars based in United States, Georgia and United Kingdom. Rajeev Shrimali's co-authors include Dhanalakshmi Chinnasamy, Steven A. Rosenberg, Nicholas P. Restifo, Zhiya Yu, Marc R. Theoret, Vadim N. Gladyshev, Dolph L. Hatfield, Bradley A. Carlson, Robert Irons and Jin Mo Park and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Cancer Research.

In The Last Decade

Rajeev Shrimali

23 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

2010 518 citations Rajeev Shrimali, Zhiya Yu et al. Cancer Research profile →

Peers

Countries citing papers authored by Rajeev Shrimali

Since Specialization

Citations

This map shows the geographic impact of Rajeev Shrimali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajeev Shrimali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajeev Shrimali more than expected).

Fields of papers citing papers by Rajeev Shrimali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajeev Shrimali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajeev Shrimali. The network helps show where Rajeev Shrimali may publish in the future.

Co-authorship network of co-authors of Rajeev Shrimali

This figure shows the co-authorship network connecting the top 25 collaborators of Rajeev Shrimali. A scholar is included among the top collaborators of Rajeev Shrimali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rajeev Shrimali. Rajeev Shrimali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy 2019 ·Molecular Cancer Therapeutics ·Pottayil G. Sasikumar, Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dodderi S. Samiulla, Krishnaprasad Subbarao, Rashmi Nair, Rajeev Shrimali, (unknown), Murali Ramachandra	55
2	Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod 2018 ·Cancer Immunology Research ·(unknown), Mikayel Mkrtichyan, Shamim Ahmad, Mason Webb, Eslam Mohamed, (unknown), (unknown), Rajeev Shrimali, Rasha Abu Eid, Scott A. Hammond, John E. Janik, Samir N. Khleif	14
3	Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy 2017 ·Cancer Research ·Shamim Ahmad, Rasha Abu Eid, Rajeev Shrimali, Mason Webb, Vivek Verma, (unknown), (unknown), Raed Samara, Paulo C. Rodrı́guez, Mikayel Mkrtichyan, Samir N. Khleif	87
4	Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition 2017 ·Cancer Research ·Rasha Abu Eid, Shamim Ahmad, (unknown), Mason Webb, (unknown), Rajeev Shrimali, Takumi Kumai, Sudha Ananth, Paulo C. Rodrı́guez, Esteban Celis, John E. Janik, Mikayel Mkrtichyan, Samir N. Khleif	61
5	Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis 2017 ·Cancer Immunology Research ·Rajeev Shrimali, Shamim Ahmad, Vivek Verma, Peng Zeng, Sudha Ananth, Pankaj Gaur, Rachel M. Gittelman, Erik Yusko, Catherine Sanders, Harlan Robins, Scott A. Hammond, John E. Janik, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif	117
6	Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy 2017 ·Journal for ImmunoTherapy of Cancer ·Rajeev Shrimali, Shamim Ahmad, (unknown), (unknown), (unknown), (unknown), Robert G. Petit, Seema Gupta, Mikayel Mkrtichyan, Samir N. Khleif	20
7	Programmed Death-1 & its Ligands: Promising Targets for Cancer Immunotherapy 2015 ·Immunotherapy ·Rajeev Shrimali, John E. Janik, Rasha Abu Eid, Mikayel Mkrtichyan, Samir N. Khleif	17
8	Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform 2014 ·Journal for ImmunoTherapy of Cancer ·Shamim Ahmad, Mikayel Mkrtichyan, Rasha Abu Eid, Rajeev Shrimali, (unknown), Samir N. Khleif	3
9	A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events 2013 ·Journal for ImmunoTherapy of Cancer ·Pottayil G. Sasikumar, Rajeev Shrimali, (unknown), Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), Murali Ramachandra	14
10	Abstract 1231: Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway. 2013 ·Cancer Research ·Pottayil G. Sasikumar, (unknown), Rajeev Shrimali, Raghuveer Ramachandra, (unknown), (unknown), (unknown), Dodderi S. Samiulla, Murali Ramachandra	1
11	Abstract 2850: Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway 2012 ·Cancer Research ·Pottayil G. Sasikumar, (unknown), Rajeev Shrimali, Krishnaprasad Subbarao, Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dodderi S. Samiulla, Murali Ramachandra	12
12	Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice 2010 ·Journal of Clinical Investigation ·Dhanalakshmi Chinnasamy, Zhiya Yu, Marc R. Theoret, Yangbing Zhao, Rajeev Shrimali, Richard A. Morgan, Steven A. Feldman, Nicholas P. Restifo, Steven A. Rosenberg	205
13	Prevention of Interleukin-2 Withdrawal-Induced Apoptosis in Lymphocytes Retrovirally Cotransduced With Genes Encoding an Antitumor T-cell Receptor and an Antiapoptotic Protein 2010 ·Journal of Immunotherapy ·Anusha Kalbasi, Rajeev Shrimali, Dhanalakshmi Chinnasamy, Steven A. Rosenberg	18
14	Role of selenium-containing proteins in T-cell and macrophage function 2010 ·Proceedings of The Nutrition Society ·Bradley A. Carlson, Min‐Hyuk Yoo, Rajeev Shrimali, Robert Irons, Vadim N. Gladyshev, Dolph L. Hatfield, Jin Mo Park	103
15	Selenoproteins Mediate T Cell Immunity through an Antioxidant Mechanism 2008 ·Journal of Biological Chemistry ·Rajeev Shrimali, Robert Irons, Bradley A. Carlson, Yasuyo Sano, Vadim N. Gladyshev, Jin Mo Park, Dolph L. Hatfield	123
16	Selective Restoration of the Selenoprotein Population in a Mouse Hepatocyte Selenoproteinless Background with Different Mutant Selenocysteine tRNAs Lacking Um34 2007 ·Journal of Biological Chemistry ·Bradley A. Carlson, Mohamed E. Moustafa, Aniruddha Sengupta, Ulrich Schweizer, Rajeev Shrimali, Mahadev Rao, (unknown), Shulin Wang, Lionel Feigenbaum, Byeong Jae Lee, Vadim N. Gladyshev, Dolph L. Hatfield	52
17	Selenoprotein deficiency adversely affects T cell development, proliferation, TCR signaling and cell mediated immunity 2007 ·The FASEB Journal ·Rajeev Shrimali, Robert Irons, Bradley A. Carlson, (unknown), Dolph L. Hatfield	1
18	Selenoprotein expression is essential in endothelial cell development and cardiac muscle function 2006 ·Neuromuscular Disorders ·Rajeev Shrimali, James Weaver, Georgina Miller, Matthew F. Starost, Bradley A. Carlson, Sergey V. Novoselov, Easwari Kumaraswamy, Vadim N. Gladyshev, Dolph L. Hatfield	28
19	Selenocysteine tRNA identification in the model organisms Dictyostelium discoideum and Tetrahymena thermophila 2005 ·Biochemical and Biophysical Research Communications ·Rajeev Shrimali, Alexey V. Lobanov, Xue-Ming Xu, Mahadev Rao, Bradley A. Carlson, Dana C. Mahadeo, Carole A. Parent, Vadim N. Gladyshev, Dolph L. Hatfield	16
20	Integrins and disintegrins: the candidate molecular players in sperm-egg interaction. 2000 ·PubMed ·Rajeev Shrimali, K.V.R. Reddy	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact